Nasdaq
$2.85▲ 1.06%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $17.9MShares out 6.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
31- 1d agoAfter-hours26.10.24 05:30DEF 14AOther#●●●#●●●#●●●
bioAffinity Technologies, Inc.
bioAffinity Technologies will hold a Special Meeting of Stockholders on November 20, 2026, to approve the issuance of shares upon the exercise of warrants from its August and October private placements and to reduce authorized shares from 350 million to 200 million. These proposals are intended to comply with Nasdaq listing rules and adjust the company's capital structure, with stockholders of record as of September 23, 2026, eligible to vote.…more
$2.85+1.06%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.15Regular26.10.15 22:308-KKey event
bioAffinity Technologies, Inc.
bioAffinity Technologies will present on the clinical role of its 'CyPath Lung' diagnostic test and new research data regarding asthma and COPD at the CHEST 2026 conference on October 21, 2026. Additionally, the company will convene its Medical and Scientific Advisory Board during the conference to discuss the expansion of CyPath Lung into the federal healthcare system and ongoing clinical studies.…more
$2.85+1.06%vs prev closeView filingShare - 10.13Pre-market26.10.13 22:238-KKey event
bioAffinity Technologies, Inc.
bioAffinity Technologies will present new research data at CHEST 2026 on October 20-21, focusing on sputum-based diagnostic tests for characterizing lung inflammation and detecting biologic drug targets in asthma and COPD. The research leverages the company's proprietary AI platform, previously used for its CyPath Lung diagnostic, to advance precision medicine and patient monitoring capabilities.…more
$2.85+1.06%vs prev closeView filingShare
30 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.13Pre-market26.10.13 21:02#●●●#●●●
bioAffinity Technologies to Present Lung Inflammation Diagnostic Data at CHEST 2026…more
bioAffinity Technologies will present new research on its sputum-based diagnostic tests for lung inflammation at the upcoming CHEST 2026 conference. The study utilizes the company's proprietary AI platform to potentially identify patients suitable for specific biologic therapies for asthma and COPD.…more
$2.85+1.06%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.8Regular26.10.09 01:10
●●●●●●●● ●●●●● ●●●●●●
bioAffinity Technologies has entered into a definitive agreement to raise approximately $4 million through a registered direct offering of common stock at $6.122 per share. The company plans to use the proceeds for working capital and to support the commercial growth of its CyPath Lung diagnostic test.…more
$2.85+1.06%vs prev closeShareBenzinga - 10.8Pre-market26.10.08 21:02
●●●●●●●● ●●●●● ●●●●●●
bioAffinity Technologies announced that the Japan Patent Office intends to grant a patent for its CyPath lung cancer diagnostic test. This development strengthens the company's intellectual property protection as it looks toward the Japanese market.…more
$2.85+1.06%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report